摘要肿瘤化疗药物在使用过程中最常见不良反应是恶心、呕吐，这就是通常说的化疗引起的恶心呕吐（Chemotherapyinduced nausea and vomiting, CINV）。这一不良反应使得肿瘤患者的依从性降低，导致肿瘤控制不理想，严重时会引起脱水、代谢紊乱、营养不良以及吸入性肺炎。因此通过使用药物来预防或减少CINV的发生成为肿瘤病人支持治疗的重要内容。
1Guideline on non-clinical and clinical development of medical products for the prevention of nausea and vomiting associated with cancer chemotherapy [ C ]. European Medicine Agency ,2006,2-9
2Jorn Herrstedt. The MASCC Evidence Based Clinical Guidelines for Antiemesis [ C]. UICC World Cancer Congress, 2006,29-30
3Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology : Update 2006 [ J ]. Clin 0ncol,2006, 24( 18 ) :2932-2947
4Roila F,Hesketh PJ,Herrstedt J, et al. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetie Consensus Conference [ J ]. Ann Oncol,2006,17 ( 1 ) : 20-28
5NCCN Clinical Practice Guidelines in Oncology : Antiemesis, V. 1. 2007 [ S ]. 1
6Jordan K, Hinke A,Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis [J]. Support Care Cancer,2007,15 : 1023-1033
7Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetren regimen, both with dexamethasone, for antiemetic efficacy in high-dose eisplatin treatment [J]. Ann Oncol, 2006, 17 (6) :1000-1006
9Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy : Dosing, efficacy, and tolerability analysis [ J ]. Ann Oncol, 2007, 18(2) :233-240
10Warr DG, Hesketh PJ, Gralla RJ, et al, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy [J]. Clin Oncol,2005, 23(12) :2822-2830
